Optimal number of lymph node stations associated with improved survival among patients with non-small cell lung cancer (NSCLC).

Authors

null

Meredith Ray

University of Memphis, School of Public Health, Memphis, TN

Meredith Ray , Anberitha T Matthews , Olawale Akinbobola , Matthew Smeltzer , Carrie Fehnel , Nicholas R Faris , Andrea Saulsberry , Kourtney Dortch , Samuel Muhit , Raymond U. Osarogiagbon

Organizations

University of Memphis, School of Public Health, Memphis, TN, Baptist Cancer Center, Multidisciplinary Thoracic Oncology Department, Memphis, TN, Baptist Memorial Health Care Corp, Memphis, TN, Baptist Memorial Healthcare System, Memphis, TN, Baptist Cancer Center, Memphis, TN, University of Memphis, Memphis, TN, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: Good quality pathologic nodal evaluation is associated with improved long-term survival in NSCLC after surgical resection. However, there is no universal definition of quality. We examined the association between number of lymph node stations (NLNS) sampled and overall survival. Methods: We examined the population-based Mid-South Quality of Surgical Resection (MS-QSR) cohort, excluding patients with neoadjuvant therapy, positive margins, and secondary resections. We summarized demographic and clinical characteristics with appropriate statistics. We employed four Cox regression models: 1) including NLNS as the only predictor; 2) model 1, adjusting for age, sex, histology, clinical stage, extent of resection, and surgical technique; 3) examined the impact of pathologic staging (pStage in 3 groups: IA/IB[<4cm tumor size]; IB[>4cm]/II/IIIA[pN2-]; pN2]) by modeling interaction with pStage and NLNS; 4) model 3 plus adjustments (no clinical stage). In a cut point analysis to identify the optimal NLNS for improved survival, we dichotomized the NLNS for cut points 0 to 12. Hazard ratios (HR) were calculated (as above) and plotted for each dichotomization. Results: The 3916 eligible patients were 21% Black, 54% male, 15% on Medicaid and 49% Medicare; 84% and 85% had clinical and pathologic stage I/II, respectively; 84% had no invasive staging; 84% had a PET-CT scan. For every additional lymph node station sampled, the HR decreased by 0.94 (95% confidence interval: 0.92, 0.96). After adjustments, the HR remained significant (Table). Our pStage cohorts comprised of 2474 (64%) IA/IB[<4cm]; 1080 (28%) IB[>4cm]/II/IIIA[pN2-]; and 290 (8%) pN2+. Once stratified, HRs remained significant among those with early stage but not for pN2+ (Table). When further adjusted, only pStage IA/IB[<4cm] patients had a significant HR, 0.94 (0.91, 0.97). The cut point analysis indicated sequential survival improvement up to ≥ 7 total stations sampled, consistently across all models/adjustments. Conclusions: The number of lymph node stations examined is directly associated with survival after lung cancer resection. Examination of a total of 7 intrapulmonary, hilar and mediastinal stations seems optimal. Hazard ratios (95% confidence intervals) for modeling hazards as a function of lymph node stations sampled (model 1), further adjusted for age, sex, histology, clinical stage, extent of resection, and surgical technique (model 2), including interaction with pathologic stage with no adjustments (model 3), and interaction with pathological stage with adjustments (no clinical stage) (model 4).

All LN Stations
Model 1:0.94 (0.92, 0.96)
Model 2:0.97 (0.95, 1)
Model 3: IA/IB[<4cm]0.9 (0.88, 0.93)
IB>4cm/II/IIIA[pN2-]0.94 (0.9, 0.98)
pN2+1.03 (0.94, 1.12)
Model 4: IA/IB[<4cm]0.94 (0.91, 0.97)
IB>4cm/II/IIIA[pN2-]0.97 (0.93, 1.01)
pN2+1.07 (0.98, 1.17)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8571)

DOI

10.1200/JCO.2023.41.16_suppl.8571

Abstract #

8571

Poster Bd #

198

Abstract Disclosures

Similar Abstracts

First Author: Sreeram Ramagopalan

Abstract

2021 ASCO Annual Meeting

Non-small cell lung cancer population mortality and stage shift.

First Author: Parth Bhargav Patel